ArticleProstate cancer and prostatic diseases2024
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors.
Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.Prostate cancer and prostatic diseases · 2026Article
- Systematic versus perilesional sampling in transperineal MRI-fusion biopsy: is perilesional sampling ready for prime time? A high-volume center analysis.World journal of surgical oncology · 2026Article
- Impact of omitting contralateral systematic biopsy on clinically significant upgrading at radical prostatectomy: a retrospective paired-design study.International urology and nephrology · 2026Article
- A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location.Prostate cancer and prostatic diseases · 2026Review
- Prostate biopsy: evolving strategies and perspectives.Prostate cancer and prostatic diseases · 2026Article
- Safety and efficacy of WVTT (Rezum) in young men: preliminary data.International urology and nephrology · 2025Article
- Biopsy strategies in the era of mpMRI: a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
- The times have changed. Let the urologists change!Prostate cancer and prostatic diseases · 2025Article
- Targeted and perilesional biopsy: triumphs and cautions.Prostate cancer and prostatic diseases · 2025Article
- Optimizing the strategies to perform prostate biopsy in MRI-positive patients: a systematic review and network meta-analysis.EClinicalMedicine · 2025Article
- Assessing Micturition, sexual function, and endoscopic outcomes one year after Aquablation: a single center prospective study.World journal of urology · 2024Article
- Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study.World journal of urology · 2024Article
- A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.BMC urology · 2024Article
- Article
- Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience.World journal of urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent prostate biopsy (PBx) protocol for prostate cancer (PCa) diagnosis is to perform systematic biopsies (SBx) combined with targeted biopsies (TBx) in case of positive MRI (i.e. PI-RADS ≥ 3). To assess the utility of performing SBx in combination with TBx, we determined the added value of SBx brought to the diagnosis of PCa according to their sextant location and MRI target characteristics.
methodsIn our local prospectively collected database, we conducted a single-center retrospective study including all patients with a suspicion of PCa, who underwent transrectal ultrasound-guided (TRUS) prostate biopsies (PBx) with a prior MRI and a single lesion classified as PI-RADS ≥ 3. We have characterized the SBx according to their location on MRI: same sextant (S-SBx), adjacent sextant (A-SBx), ipsilateral side (I-SBx) and contralateral side (C-SBx). The added value of SBx and TBx was defined as any upgrading to significant PCa (csPCa) (ISUP ≥2).
results371 patients were included in the study. The added value of SBx was 10% overall. Regarding the lesion location and the SBx sextant, the added value of SBx was: 5.1% for S-SBx, 5.4% for A-SBx, 4.9% for I-SBx and 1.9% for C-SBx. The overall added value of SBx was 6.8% for PI-RADS 3 lesions, 14% for PI-RADS 4 lesions and 6.7% for PI-RADS 5 lesions (p = 0.063). The added value of SBx for contralateral side was 1.9% (2/103), 3.1% (5/163) and 0% (0/105) for PI-RADS 3, PI-RADS 4 and PI-RADS 5 lesions, respectively (p = 0,4). The added value of SBx was lower when the number of TBx was higher (OR 0.57; CI 95% 0.37-0.85; p = 0.007).
conclusionsOur results suggest that the utility of performing SBx in the contralateral lobe toward the MRI lesion was very low, supporting that they might be avoided.
Indexed as
Identifiers
38114598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.